Physician profile
Dawn Malene
NPI 1912015694
$1,116.85
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $218 · 2021: $18.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.50 | 2019-2020 | |
| Amgen INC. | $213.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $146.97 | 2019-2020 | |
| Pfizer INC. | $98.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.07 | 2019-2020 | |
| Allergan, INC. | $70.06 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $53.78 | 2019-2020 | |
| Abbvie INC. | $45.93 | 2019-2021 | |
| Eisai INC. | $33.47 | 2019 | |
| Lilly USA, LLC | $25.09 | 2019 | |
| Glaxosmithkline, LLC. | $22.62 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.07 | 2019 | |
| Sanofi Pasteur INC. | $17.41 | 2019 | |
| Roche Diagnostics Corporation | $14.76 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.51 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.36 | 2020 | |
| Promius Pharma LLC | $11.31 | 2019 | |
| Merck Sharp & Dohme LLC | $11.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Malene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.